32 recruiting. 32 Phase 1, 28 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 32 | Recruiting 32 |
| Phase 2 | 28 | Recruiting 28 |
Follow Beijing Biotech: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer ETB-DualNK-01, Fludarabine, Cyclophosphamide - Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma | Phase 1 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-06-11 |
| Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma EB-MF-CAR-NK-01, Fludarabine, Cyclophosphamide - Malignant Pleural Mesotheliomas | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-04-06 |
| Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide - Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 30 | 2026-03-02 | 2026-03-30 |
| EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC EGFR/HER2 Dual-Target CAR-NK Cells, Fludarabine, Cyclophosphamide - Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Biomarker-positive EGFR/HER2- Expressing HNSCC | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 42 | 2026-03-02 | 2026-06-01 |
| Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer EB-HC01 dual-target CARNK cells, Fludarabine, Cyclophosphamide - Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 30 | 2026-03-02 | 2026-06-11 |
| Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma Dual-target CAR-NK cells, Cyclophosphamide, Intracranial catheter/reservoir for locoregional delivery - Malignant Glioma, High-Grade Gliomas | Phase 1 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-04-24 |
| Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells, Fludarabine, Cyclophosphamide - Unresectable Melanoma, Metastatic Cutaneous Melanoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-06-04 |
| Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma Cyclophosphamide, Fludarabine, EB-CAR30-NK - B2 Thymoma, Thymic Carcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-05-20 |
| Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC Dual-target CAR-NK cells, Lymphodepleting chemotherapy, Supportive care - Non-Small Cell Lung Cancer, Advanced/Metastatic | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 60 | 2026-03-02 | 2026-06-11 |
| Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma EB-DTNB-NK, Fludarabine, Cyclophosphamide - Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-03-30 |
| PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors EB-PT-CAR-NK-S, EB-PT-CAR-NK-D, Lymphodepleting chemotherapy - Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 60 | 2026-03-02 | 2026-04-06 |
| Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 Dual-target CAR-NK cell product, Cyclophosphamide, supportive - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-06-01 |
| Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors Autologous dual-target CAR-T cells selected from the predefined target library., Fludarabine, Cyclophosphamide - Advanced Unresectable, Metastatic | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 72 | 2026-03-02 | 2026-04-13 |
| Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors EB-NK-301, Fludarabine - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 60 | 2026-03-02 | 2026-05-15 |
| Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer EB-DUALNK, Cyclophosphamide, Fludarabine - Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 42 | 2026-03-02 | 2026-05-15 |
| Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma EB-DT-NK-UC101, Cyclophosphamide, Fludarabine - Bladder Cancer, Urothelial Carcinoma | Phase 1 | Recruiting | Beijing Biotech | 42 | 2026-03-02 | 2026-03-25 |
| Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer EB-DT-CAR-NK, Fludarabine, Cyclophosphamide - Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-04-24 |
| Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1), Lymphodepleting chemotherapy (Flu/Cy) - Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 42 | 2026-03-02 | 2026-06-04 |
| Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma EBNK-1822H2 dual-target CLDN18.2/HER2 CAR-NK cells, Fludarabine, Cyclophosphamide - Recurrent or Metastatic Esophageal Adenocarcinoma, Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-06-03 |
| Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) EB-DART-NK01, Lymphodepleting chemotherapy - Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 60 | 2026-03-02 | 2026-08-04 |
Showing 20 of 32. Sign in to see all of them.
Recurrence (8) · Neoplasm Metastasis (6) · Ovarian Neoplasms (4) · Carcinoma, Ovarian Epithelial (3) · Glioblastoma (3) · Pancreatic Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Fallopian Tube Neoplasms (2) · Glioma (2) · Prostatic Neoplasms (2) · Small Cell Lung Carcinoma (2) · Stomach Neoplasms (2) · Adenocarcinoma Of Esophagus (1)
fludarabine (21) · Cyclophosphamide (20) · Palliative Care (5) · fludarabine phosphate (4) · Influenza Vaccines (2) · Transplantation Conditioning (2) · AP 1903 reagent (1)
China (32)